The antibacterial effect of nanosilver fluoride in relation to caries activity in primary teeth: a protocol for a randomized controlled clinical trial

• Published in: Current controlled trials in cardiovascular medicine 2022-07, Vol.23 (1), p.558-11, Article 558
• Main Authors: Ammar, Nour, El-Tekeya, Magda M, Essa, Sara, Essawy, Marwa M, El Achy, Samar N, Talaat, Dalia M
• Format: Article
• Language: English
• Subjects: Agar - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibacterial; Antibacterial agents; Antibiotics; Care and treatment; Caries; Child; Child, Preschool; Clinical trials; Culture Media - pharmacology; Cytotoxicity; Dental caries; Dental Caries - drug therapy; Dentistry; Dosage and administration; Fibroblasts; Fluoride treatment; Fluorides; Fluorides, Topical - therapeutic use; Humans; Microbiology; Nanoparticles; Nanosilver fluoride; Pediatrics; Polyethylene glycol; Quaternary Ammonium Compounds - therapeutic use; Randomized Controlled Trials as Topic; Saliva; Silver; Silver diamine fluoride; Study Protocol; Teeth; Testing; Tooth, Deciduous
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-022-06477-5

Minimally invasive dentistry is a highly convenient and efficient method of managing caries in pediatric patients. Silver diamine fluoride (SDF) is commonly used to arrest active caries lesions. However, the associated black stain, possibility of soft tissue injury, and unpleasant taste often limit its use. Recently, nanosilver fluoride (NSF) emerged as a promising topical fluoride agent with potent cariostatic and antibacterial potentials. This novel anticaries agent has gained attention as an alternative to overcome the drawbacks of SDF in caries arrest. To assess the antibacterial effect of NSF in relation to caries activity in dentin caries lesions, as well as to investigate the change in saliva bacterial levels in primary teeth in comparison to SDF after 1 and 3 months. Fifty children aged 4 to 6 years old with active dentin caries lesions (score 5 according to International Detection and Assessment System (ICDAS II) criteria) will be enrolled in the study. They will be equally and randomly allocated into 2 groups: a group receiving NSF and a control group receiving SDF treatment. Microbiological samples will be collected from the carious lesions and from unstimulated saliva at the baseline and at the 1 and 3 months' follow-up appointments. Bacterial counts will be assessed using Mitis Salivarius agar (selective culture media for S. mutans) and Rogosa agar (selective culture media for lactobacilli), and the results will be expressed in colony-forming units. Data regarding the children's oral health will be collected and their dmf index will be scored. The arrest of active carious lesions will be measured at the follow-up appointments according to ICDAS II criteria. The relation between bacterial colony counts and lesion activity for both groups will be assessed, as well as the change in salivary bacterial counts. The collected data will be statistically evaluated and tabulated. This clinical trial has been registered on ClinicalTrials.gov in January 2022 (original version) with ID: NCT05221749.